Discovery and validation of circulating miRNAs for the clinical prognosis of severe dengue.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
02
03
2022
accepted:
21
09
2022
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
20
10
2022
Statut:
epublish
Résumé
Early prognostic markers of severe dengue may improve case management and reduce dengue-related mortalities. This study aimed to identify circulating microRNAs (miRNAs) as biomarkers for predicting severe dengue. Serum samples from dengue-infected patients were collected on the first day of admission. Patients were followed up for 14 days after admission to determine the final diagnosis. Participants were divided into non-severe and severe dengue, as defined by WHO 2009 criteria. Circulating microtranscriptome analysis was performed using NanoString miRNA Expression Assay. The expression level of candidate miRNAs were then validated by quantitative reverse transcription-PCR method. The discovery cohort (N = 19) lead to the identification of 37 differentially expressed miRNAs between the two groups. Six up-regulated candidate miRNAs were selected and further validated in the larger cohort (N = 135). MiR574-5p and miR1246 displayed the highest diagnostic performance in discriminating between severe from non-severe dengue (ROC-AUC = 0.83). Additionally, miR574-5p and miR1246 had high sensitivity and high negative predictive value for detecting severe dengue. Multivariate analysis suggested that serum miR574-5p was an independent predictor of severe dengue (odds ratio 3.30, 95% CI 1.81-6.04; p<0.001). Our study indicated that circulating miRNAs, especially miR-574-5p and miR-1246, might be a promising diagnostic and prognostic biomarker for severe dengue upon hospital admission, especially when using these biomarkers on days 1 to 2 before the onset of severe dengue complications.
Sections du résumé
BACKGROUND
Early prognostic markers of severe dengue may improve case management and reduce dengue-related mortalities. This study aimed to identify circulating microRNAs (miRNAs) as biomarkers for predicting severe dengue.
METHODOLOGY
Serum samples from dengue-infected patients were collected on the first day of admission. Patients were followed up for 14 days after admission to determine the final diagnosis. Participants were divided into non-severe and severe dengue, as defined by WHO 2009 criteria. Circulating microtranscriptome analysis was performed using NanoString miRNA Expression Assay. The expression level of candidate miRNAs were then validated by quantitative reverse transcription-PCR method.
PRINCIPAL FINDINGS
The discovery cohort (N = 19) lead to the identification of 37 differentially expressed miRNAs between the two groups. Six up-regulated candidate miRNAs were selected and further validated in the larger cohort (N = 135). MiR574-5p and miR1246 displayed the highest diagnostic performance in discriminating between severe from non-severe dengue (ROC-AUC = 0.83). Additionally, miR574-5p and miR1246 had high sensitivity and high negative predictive value for detecting severe dengue. Multivariate analysis suggested that serum miR574-5p was an independent predictor of severe dengue (odds ratio 3.30, 95% CI 1.81-6.04; p<0.001).
CONCLUSION
Our study indicated that circulating miRNAs, especially miR-574-5p and miR-1246, might be a promising diagnostic and prognostic biomarker for severe dengue upon hospital admission, especially when using these biomarkers on days 1 to 2 before the onset of severe dengue complications.
Identifiants
pubmed: 36251659
doi: 10.1371/journal.pntd.0010836
pii: PNTD-D-22-00270
pmc: PMC9576100
doi:
Substances chimiques
Biomarkers
0
Biomarkers, Tumor
0
Circulating MicroRNA
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0010836Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Arterioscler Thromb Vasc Biol. 2011 May;31(5):980-5
pubmed: 21508344
Int J Med Sci. 2016 Feb 18;13(3):195-205
pubmed: 26941580
Southeast Asian J Trop Med Public Health. 2015;46 Suppl 1:79-98
pubmed: 26506734
Mol Med Rep. 2015 Jul;12(1):615-22
pubmed: 25738263
RNA Biol. 2012 Jun;9(6):742-50
pubmed: 22664920
Adv J Emerg Med. 2019 May 19;3(3):e33
pubmed: 31410410
Int J Mol Sci. 2019 Sep 05;20(18):
pubmed: 31491899
Life Sci. 2021 Jul 15;277:119501
pubmed: 33862108
BMJ Open. 2020 Sep 13;10(9):e035120
pubmed: 32928847
J Clin Virol. 2015 Feb;63:25-31
pubmed: 25600599
Mol Oncol. 2016 Jun;10(6):895-909
pubmed: 27038552
Eur J Immunol. 2020 Mar;50(3):342-352
pubmed: 31743425
PLoS Negl Trop Dis. 2020 Dec 23;14(12):e0008960
pubmed: 33362244
Nature. 2005 Feb 17;433(7027):769-73
pubmed: 15685193
J Biomed Sci. 2015 Oct 14;22:83
pubmed: 26462910
J Clin Microbiol. 1992 Mar;30(3):545-51
pubmed: 1372617
RNA Biol. 2012 Feb;9(2):137-42
pubmed: 22258222
Genes Dev. 2011 Sep 15;25(18):1881-94
pubmed: 21896651
Lancet Infect Dis. 2021 Jul;21(7):1014-1026
pubmed: 33640077
Nat Rev Immunol. 2007 Mar;7(3):179-90
pubmed: 17318230
J Infect Dis. 2018 May 5;217(11):1690-1698
pubmed: 29490079
PLoS Negl Trop Dis. 2021 Oct 5;15(10):e0009808
pubmed: 34610027
PLoS Negl Trop Dis. 2014 Aug 14;8(8):e3088
pubmed: 25122182
mSystems. 2020 Sep 15;5(5):
pubmed: 32934118
Radiology. 1983 Sep;148(3):839-43
pubmed: 6878708
Nat Struct Mol Biol. 2012 Jun 05;19(6):586-93
pubmed: 22664986
Mediators Inflamm. 2015;2015:313842
pubmed: 25999666
Nature. 2013 Apr 25;496(7446):504-7
pubmed: 23563266
Cell Physiol Biochem. 2018;45(1):301-318
pubmed: 29402802
Cancer Res Treat. 2019 Oct;51(4):1420-1429
pubmed: 30913872
BMC Med. 2014 Sep 04;12:147
pubmed: 25259615
Int Heart J. 2021 Sep 30;62(5):1112-1123
pubmed: 34544967
Mol Med Rep. 2013 Mar;7(3):791-8
pubmed: 23354650
Exp Ther Med. 2021 Apr;21(4):350
pubmed: 33732323
PLoS One. 2012;7(10):e46890
pubmed: 23071657
J Proteome Res. 2009 Jan;8(1):113-7
pubmed: 19072545
J Med Assoc Thai. 2015 Jan;98 Suppl 1:S118-22
pubmed: 25764623
PLoS Pathog. 2019 Apr 22;15(4):e1007625
pubmed: 31009511
Cell. 2006 Feb 24;124(4):783-801
pubmed: 16497588
Ann Clin Biochem. 2016 Jul;53(Pt 4):466-76
pubmed: 26290515
Arch Physiol Biochem. 2022 Aug;128(4):875-879
pubmed: 32141790
EMBO Rep. 2018 Aug;19(8):
pubmed: 29880709
Viral Immunol. 2016 Mar;29(2):95-104
pubmed: 26709547
Stat Med. 1997 Jul 15;16(13):1529-42
pubmed: 9249923
Mol Oncol. 2020 Mar;14(3):520-538
pubmed: 31930767
Sci Transl Med. 2015 Sep 9;7(304):304ra142
pubmed: 26355031
Cell Rep. 2019 Jan 29;26(5):1104-1111.e4
pubmed: 30699342
J Clin Microbiol. 2007 Aug;45(8):2480-5
pubmed: 17522268
Indian J Hematol Blood Transfus. 2011 Sep;27(3):127-30
pubmed: 22942561
PLoS One. 2012;7(11):e48278
pubmed: 23133627
PLoS Negl Trop Dis. 2013 Sep 26;7(9):e2412
pubmed: 24086778
Lancet. 1998 Sep 19;352(9132):971-7
pubmed: 9752834
Epigenomics. 2021 Aug;13(16):1315-1325
pubmed: 34498489